Guardant Health, Inc. cotiza a 162.98 USD y tiene una capitalización bursátil de $21.9B. En los últimos 12 meses ha facturado $1.2B con un margen de flujo de caja libre del -23.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommen…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.42 | $-0.45 | $-0.50 |
| Estimado | $-0.32 | $-0.39 | $-0.47 | $-0.47 |
| Sorpresa | — | -7.7% | +4.3% | -6.4% |
| Métrica | GH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 64.5% | 57.0% | +7.4% |
| Operating Margin | -44.5% | -38.6% | -5.9% |
| Net Margin | -42.4% | -33.6% | -8.8% |
| FCF Margin | -23.7% | -13.9% | -9.9% |
| ROE | — | -40.4% | — |
| ROA | -20.7% | -32.0% | +11.3% |
| Current Ratio | 4.84 | 2.84 | +2.00 |
| Debt / Equity | -15.14 | 0.28 | -15.42 |